前列地尔治疗失代偿期肝硬化42例疗效观察

目的：观察前列地尔治疗失代偿期肝硬化的疗效。方法：对2007年2月到2008年2月入院的失代偿期肝硬化期肝硬化患者，按入院次序，查阅随机数字表分为治疗组和对照组，均给予支持、保肝、利尿治疗，治疗组加输前列地尔100μg＋5％葡萄糖液250mL，每日1次，疗程2周。以治疗前后ALT，AST，前自蛋白，24小时尿量，腹围，B超下腹水深度为观察指标。结果：治疗2周后，治疗组与对照组比较，AST，ALT，腹围及腹水深度显著下降，而前白蛋白及24小时尿量显著升高。结论：前列地尔治疗失代偿期肝硬化疗效显著，副作用少。值得临床推广应用。

Effects of Alprostadil on Decompensated Liver Cirrhosis 42 Cases Reported

Objective：To observe the therapeutic efficacy of alprostadil on patients with liver cirrhosis. Methods：According to the order to hospital and random digital table, the inpatients with liver cirrhosis hopitalized from February 2007 to February 2008 were devided into two groups： the alprostadil treatment group and control group. Both groups were treated with supporting drugs, protection liver drugs and diuretic, in addition, the treatment group also received treatment with 200ul alprostadil daily for two weeks. The changes of ALT,AST,pro-ALB,urine volume in 24 hours,ab- dominal perimeter and the deepth of ascite were observed after two-week treatment. Results： After two weeks, the volume of AST,ALT,abdominal perimeter and the deepth of ascite in alprostadil treatment group decreased significantly while pro-ALB, urine volume in 24 hours increased drematieally. Conclusion：These reswhs suggested that alprostadil was of therapeutic afficacy on liver cirrhosis with little side effects.